APML comprises approximately 5-8% of all Acute Myeloblastic Leukaemia (AML) and is seen mostly in middle aged individuals but can present at any age. It is amongst the most curable malignancies with survival close to 80%. Combination of all-trans-retinoic-acid (ATRA) and anthracyclines is the current standard of care for APML patient. Combination of ATRA and ATO in this case show better response.
A 60 years old male patient having diabetes and CKD reported to E&C department of CMH Dhaka with complaints of progressive worsening of generalized weakness, low grade intermittent fever and occasional gum bleeding for 01 month. Subsequently he was diagnosed as a case of Acute Promyelocytic Leukaemia and was treated with ATRA and ATO combination therapy. Now the patient is completely well and his PML-RARA study is 0%.
Correspondence: Maj Dr Mohammad Shahidul Islam, MCPS (Cl Path), DCP, Trainee in FCPS Part II Haematology.